Cargando…

Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy

A prodrug is bioreversible medication that is specifically converted to the active drugs by enzymes overexpressed in the tumor microenvironment, which can considerably reduce the chemotherapy-induced side effects. However, prodrug strategies usually have low antitumor efficacy compared to free drugs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cho, Hanhee, Shim, Man Kyu, Moon, Yujeong, Song, Sukyung, Kim, Jinseong, Choi, Jiwoong, Kim, Jeongrae, Lee, Youngjoo, Park, Jung Yeon, Kim, Yongju, Ahn, Cheol-Hee, Kim, Mi Ra, Yoon, Hong Yeol, Kim, Kwangmeyung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9609178/ https://www.ncbi.nlm.nih.gov/pubmed/36297566 http://dx.doi.org/10.3390/pharmaceutics14102131

Ejemplares similares

Light-Activated Monomethyl Auristatin E Prodrug Nanoparticles for Combinational Photo-Chemotherapy of Pancreatic Cancer
por: Cho, In Kyung, et al.
Publicado: (2022)

Cathepsin B-Overexpressed Tumor Cell Activatable Albumin-Binding Doxorubicin Prodrug for Cancer-Targeted Therapy
por: Cho, Hanhee, et al.
Publicado: (2021)

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
por: Chang, Hsuan Ping, et al.
Publicado: (2021)

Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death
por: Moon, Yujeong, et al.
Publicado: (2022)

Sustained and Long-Term Release of Doxorubicin from PLGA Nanoparticles for Eliciting Anti-Tumor Immune Responses
por: Kim, Jeongrae, et al.
Publicado: (2022)

Preclinical development of carrier-free prodrug nanoparticles for enhanced antitumor therapeutic potential with less toxicity
por: Shim, Man Kyu, et al.
Publicado: (2022)

Bombesin-Tethered Reactive Oxygen Species (ROS)-Responsive Nanoparticles for Monomethyl Auristatin F (MMAF) Delivery
por: Kim, Jihoon, et al.
Publicado: (2021)

Implantable micro-scale LED device guided photodynamic therapy to potentiate antitumor immunity with mild visible light
por: Choi, Jiwoong, et al.
Publicado: (2022)

Doxorubicin-Loaded PLGA Nanoparticles for Cancer Therapy: Molecular Weight Effect of PLGA in Doxorubicin Release for Controlling Immunogenic Cell Death
por: Choi, Yongwhan, et al.
Publicado: (2020)

Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines
por: Abawi, Ariana, et al.
Publicado: (2021)

Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates
por: Fu, Zhiwen, et al.
Publicado: (2023)

All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy
por: Song, Sukyung, et al.
Publicado: (2023)

New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling
por: Johansson, Mikael P., et al.
Publicado: (2017)

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
por: Hingorani, Dina V., et al.
Publicado: (2022)

Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors
por: Kim, Jinseong, et al.
Publicado: (2023)

Mesenchymal Stem Cell-Mediated Deep Tumor Delivery of Gold Nanorod for Photothermal Therapy
por: Yun, Wan Su, et al.
Publicado: (2022)

Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
por: Wang, Yichen, et al.
Publicado: (2018)

Micro-syringe chip-guided intratumoral administration of lipid nanoparticles for targeted anticancer therapy
por: Kim, Jeongrae, et al.
Publicado: (2023)

Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload
por: Wang, Yanming, et al.
Publicado: (2017)

Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation
por: Cho, Hanhee, et al.
Publicado: (2022)

Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
por: Park, Min-Ho, et al.
Publicado: (2019)

Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
por: Krzyscik, Mateusz A., et al.
Publicado: (2021)

Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable cis/trans Equilibrium and Retained Cytotoxicity
por: Sokka, Iris K., et al.
Publicado: (2021)

Injectable Hydrogel-Based Combination Cancer Immunotherapy for Overcoming Localized Therapeutic Efficacy
por: Kim, Jeongrae, et al.
Publicado: (2022)

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo
por: Gallery, Melissa, et al.
Publicado: (2018)

Synthesis and Biological Evaluation of RGD and isoDGR–Monomethyl Auristatin Conjugates Targeting Integrin α(V)β(3)
por: Raposo Moreira Dias, André, et al.
Publicado: (2019)

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
por: Damiani, Isabella, et al.
Publicado: (2021)

Cancer-Specific Delivery of Proteolysis-Targeting Chimeras (PROTACs) and Their Application to Cancer Immunotherapy
por: Moon, Yujeong, et al.
Publicado: (2023)

Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors
por: Krzyscik, Mateusz Adam, et al.
Publicado: (2017)

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
por: Liu-Kreyche, Peggy, et al.
Publicado: (2019)

Synthesis and Evaluation of a Monomethyl Auristatin E—Integrin α(v)β(6) Binding Peptide–Drug Conjugate for Tumor Targeted Drug Delivery
por: Davis, Ryan A., et al.
Publicado: (2023)

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
por: Zhou, Wei, et al.
Publicado: (2023)

Bivalent EGFR-Targeting DARPin-MMAE Conjugates
por: Karsten, Lennard, et al.
Publicado: (2022)

FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
por: Świderska, Karolina Weronika, et al.
Publicado: (2018)

Old Drug, New Delivery Strategy: MMAE Repackaged
por: Lahnif, Hanane, et al.
Publicado: (2023)

Recent Studies and Progress in the Intratumoral Administration of Nano-Sized Drug Delivery Systems
por: Yun, Wan Su, et al.
Publicado: (2023)

Thiol-Responsive Gold Nanodot Swarm with Glycol Chitosan for Photothermal Cancer Therapy
por: Jo, SeongHoon, et al.
Publicado: (2021)

Guanidine-modified albumin-MMAE conjugates with enhanced endocytosis ability
por: Yi, Ce, et al.
Publicado: (2023)

Adoptive Transfer of Photosensitizer-Loaded Cytotoxic T Cells for Combinational Photodynamic Therapy and Cancer Immuno-Therapy
por: Blaudszun, André-René, et al.
Publicado: (2023)

Prediction of IGS RTS Orbit Correction Using LSTM Network at the Time of IOD Change
por: Kim, Beomsoo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bf3msmqmih28n928snibuq81n6